GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » Enterprise Value

Chong Kun Dang Pharmaceutical (XKRX:185750) Enterprise Value : ₩1,183,365 Mil (As of Jun. 09, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Chong Kun Dang Pharmaceutical's Enterprise Value is ₩1,183,365 Mil. Chong Kun Dang Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩252,527 Mil. Therefore, Chong Kun Dang Pharmaceutical's EV-to-EBIT ratio for today is 4.69.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Chong Kun Dang Pharmaceutical's Enterprise Value is ₩1,183,365 Mil. Chong Kun Dang Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩289,795 Mil. Therefore, Chong Kun Dang Pharmaceutical's EV-to-EBITDA ratio for today is 4.08.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Chong Kun Dang Pharmaceutical's Enterprise Value is ₩1,183,365 Mil. Chong Kun Dang Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩1,665,726 Mil. Therefore, Chong Kun Dang Pharmaceutical's EV-to-Revenue ratio for today is 0.71.


Chong Kun Dang Pharmaceutical Enterprise Value Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical Enterprise Value Chart

Chong Kun Dang Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,026,982.57 2,422,517.79 1,297,026.58 1,031,836.62 1,441,029.45

Chong Kun Dang Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,002,584.31 1,047,738.98 1,114,568.78 1,441,029.45 1,228,977.31

Competitive Comparison of Chong Kun Dang Pharmaceutical's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Chong Kun Dang Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chong Kun Dang Pharmaceutical's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chong Kun Dang Pharmaceutical's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Chong Kun Dang Pharmaceutical's Enterprise Value falls into.



Chong Kun Dang Pharmaceutical Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Chong Kun Dang Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Chong Kun Dang Pharmaceutical's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chong Kun Dang Pharmaceutical  (XKRX:185750) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Chong Kun Dang Pharmaceutical's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1183365.434/252526.778
=4.69

Chong Kun Dang Pharmaceutical's current Enterprise Value is ₩1,183,365 Mil.
Chong Kun Dang Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩252,527 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Chong Kun Dang Pharmaceutical's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1183365.434/289795.326
=4.08

Chong Kun Dang Pharmaceutical's current Enterprise Value is ₩1,183,365 Mil.
Chong Kun Dang Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩289,795 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Chong Kun Dang Pharmaceutical's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1183365.434/1665725.582
=0.71

Chong Kun Dang Pharmaceutical's current Enterprise Value is ₩1,183,365 Mil.
Chong Kun Dang Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,665,726 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chong Kun Dang Pharmaceutical Enterprise Value Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines